Omschrijving
To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)-a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)-face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in prog
Kenmerken
| Artikelnummer | 9200000021876118 |
|---|---|
| EAN | 9780309265959 |
| Categorie | Educational Books |
| Productgroep | Boeken |
| Segment | Textual/Printed/Reference Materials |
| Prijs Nederland | € 50,99 |
| Prijs België | € 50,99 |
| Verzendkosten NL | Gratis |
| Verzendkosten BE | Gratis |
| Levertijd Nederland | Over 57 dagen |
| Levertijd België | Over 57 dagen |
| Verkoper | Partner |
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis bestellen bij snelkeus
Koop Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis van Onbekend online in de categorie Educational Books. Prijs € 50,99, levering in Nederland · Over 57 dagen.